Service is in preparation Official β release coming soon. Some features are still being adjusted.

Investical Earnings & investing calendar Earnings & investing calendar
/
AASKA Pharmaceutical Holdings Co.,Ltd. logo
4886TSE Prime

ASKA Pharmaceutical Holdings Co.,Ltd.

あすか製薬ホールディングス Yahoo Finance

Recent & upcoming events

Aug 4
Earnings 2:00
Q1 earnings announcement (scheduled)
Add to Google Calendar
Jun 23
Shareholder meeting Time TBD
Shareholders' meeting
Add to Google Calendar
Sep 27
Est.
Dividend Time TBD
Last day with rights (interim)
Add to Google Calendar
Sep 28
Est.
Ex-dividend Time TBD
Ex-rights date (interim)
Add to Google Calendar
Nov 3
Est.
Earnings 1:00 approx.
Q2 earnings
Add to Google Calendar
2027
Feb 2
Est.
Earnings 1:00 approx.
Q3 earnings
Add to Google Calendar
Mar 28
Est.
Dividend Time TBD
Last day with rights (year-end)
Add to Google Calendar
Mar 29
Est.
Ex-dividend Time TBD
Ex-rights date (year-end)
Add to Google Calendar
May 4
Est.
Earnings 2:00 approx.
Full-year earnings
Add to Google Calendar
Aug 3
Est.
Earnings 2:00 approx.
Q1 earnings
Add to Google Calendar

KPI highlights

FY26
Revenue ¥71.13B YoY +10.9%
Operating income ¥5.83B margin 8.2%
Net income ¥5.42B YoY +6.3%
EPS ¥191 YoY +6.2%
P/E —
ROE 8.0% Equity ratio 63% Typical equity ratios vary a lot by industry. Banks, brokerages, and other financial companies tend to run lower ratios because leverage (using other people's capital) is core to their business model — a low ratio there isn't a sign of financial weakness.

Company guidance

FY2027/03 Company-issued full-year guidance (from earnings report) / %=vs prior FY
Revenue ¥73.00B +2.6%
Operating income ¥6.20B +6.3%
Net income ¥4.80B -11.5%
EPS ¥169 -11.5%

Quarterly fundamentals

Income & cash flow
Quarter FY23 Q2FY23 Q3FY23 Q4FY24 Q1FY24 Q2FY25 Q2
Revenue ¥16.02B¥15.63B¥17.18B¥14.02B——
Operating income ¥1.70B¥1.35B¥2.47B¥973M——
Net income ¥1.43B¥2.70B¥2.33B¥1.09B——
Operating CF ——————

Ownership over time

Share of total shares outstanding (disclosed major holdings + undisclosed)（2022–2026）

事業法人 14.4%国内機関 13.3%海外機関 11.8%アクティビスト 8.4%未開示 49.6%20222023202420252026
事業法人国内機関海外機関アクティビスト個人未開示・浮動株

「国内機関」は信託銀行の名義口座（年金・パッシブ・一部海外資本を含む）を集計し、実質保有者へは分解していません。分類は開示名称からの推定です。

Top shareholders — rank & share

日本マスタートラスト信託銀行株式会社 9.4%日本マスタートラスト信託銀行株式会社（信託口）NIPPON ACTIVE VALU 8.4%NIPPON ACTIVE VALUE FUND PLC（常任代理人 香港上海銀行東京支店）武田薬品工業株式会社 7.8%武田薬品工業株式会社ゼリア新薬工業株式会社 6.6%ゼリア新薬工業株式会社STATE STREET BANK 4%STATE STREET BANK AND TRUST COMPANY 505103（常任代理人 株式会社みずほ銀行決済営業部）株式会社三菱ＵＦＪ銀行 3.9%株式会社三菱ＵＦＪ銀行NAVF SELECT LLC（常任 3%NAVF SELECT LLC（常任代理人 香港上海銀行東京支店）山口隆 2.5%山口隆20222023202420252026

Top shareholders — actual figures (as of 2026)

Holder Shares held Ratio Source
日本マスタートラスト信託銀行株式会社（信託口） 2,670,000 9.4% Yuho (EDINET)
NIPPON ACTIVE VALUE FUND PLC 2,399,000 8.4% Yuho (EDINET)
武田薬品工業株式会社 2,204,000 7.8% Yuho (EDINET)
ゼリア新薬工業株式会社 1,877,000 6.6% Yuho (EDINET)
STATE STREET BANK AND TRUST COMPANY 505103 1,138,000 4.0% Yuho (EDINET)
株式会社三菱UFJ銀行 1,100,000 3.9% Yuho (EDINET)
NAVF SELECT LLC 848,000 3.0% Yuho (EDINET)
NOMURA PB NOMINEES LIMITED OMNIBUS MARGIN（CASHPB） 789,000 2.8% Yuho (EDINET)
山口隆 707,000 2.5% Yuho (EDINET)
CACEIS BANK,LUXEMBOURG BRANCH/AIF CLIENTS ASSETS 593,000 2.1% Yuho (EDINET)

Source：EDINET（大株主の状況）　Classification inferred from disclosed names

F-Score (Piotroski)

5/9

Checks financial health against 9 criteria and shows how many are met as a fraction (more ✓ marks is healthier). Items with no data are shown as “—” — they're simply excluded from judgment, not counted against the score.

✓ Positive ROA ROA 4.8%
✓ Positive operating cash flow ¥6.30B
✗ ROA improved YoY 5.1% → 4.8%
✓ Operating CF exceeds net income (accrual quality) OCF ¥6.30B / net income ¥5.42B
✗ Equity ratio improved* Substitute for the original “decrease in long-term debt” 65.0% → 62.6%
✓ Current ratio improved 2.54× → 2.76×
✓ No dilution (shares outstanding did not increase) 28,763,199 → 28,763,199
✗ Gross margin improved 48.9% → 48.0%
✗ Asset turnover improved 0.64× → 0.63×

This score is reference information based on our own financial metrics. It is NOT a credit rating issued by a credit rating agency under Article 66-27 of the Financial Instruments and Exchange Act, and is NOT investment advice or a recommendation. Make investment decisions at your own responsibility.

Fact checklist

FY26
Equity ratio 62.6%
Current ratio 2.8×
Years of positive operating CF 5 of last 5 yrs
Payout ratio 71%
Latest fiscal year result Profit (net income ¥5.42B)

Performance history

Last 10 years
0億円178億円356億円533億円711億円 FY22FY23FY24FY25FY26

Income & assets

Unit: ¥100M
Item FY22FY23FY24FY25FY26
Revenue 566605628641711
Operating income 48.051.165.053.358.3
Ordinary income 48.852.365.251.156.7
Net income 42.942.475.551.054.2
Total assets 8338719071,0051,124
Equity 489545619692768

Indicators & cash flow

Unit: ¥100M
Item FY22FY23FY24FY25FY26
EPS ¥151¥150¥267¥180¥191
ROE 8.8%8.2%13.0%8.0%8.0%
Operating CF 28.433.514.924.963.0
Investing CF 67.4-11.317.1-61.2-57.5
Financing CF -30.0-18.2-39.4-29.6-8.18
FCF 95.922.331.9-36.45.51

Source: EDINET (Annual Securities Report) (fetched 2026-08-29) *Some metrics supplemented from additional sources

Key financial metrics

3-year revenue growth ✓ Dividend grower ✓

Sector positioning

Relative standing within the sector
Is this information incorrect?

Data provided by Twelve Data